Q-omics provides the consensus-scored CTU2 profile across patient tissues and cancer cell-line models. CTU2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTU2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CTU2 RNA expression shows 17,776 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where CTU2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTU2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTU2 survival associations across molecular data types. CTU2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTU2 RNA expression–survival associations across cancer types. High CTU2 expression shows unfavorable associations in KIRC, LIHC, ACC, LGG, BLCA and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTU2 RNA expression.
This table summarizes CTU2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CTU2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTU2 shows higher tumor expression in KIRC, COAD, KIRP, HNSC, LIHC and STAD. The KIRC box plot shows higher CTU2 RNA expression in tumor versus normal tissue (log2 FC = +0.622, t-test p < 0.001).
This table shows molecular features associated with CTU2 in patient tissues and cancer cell lines. In patient samples, CTU2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTU2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
